Literature DB >> 20157292

Impairment of ultrastructure and cytoskeleton during progression of cardiac hypertrophy to heart failure.

Anasuya Gupta1, Sudhiranjan Gupta, David Young, Biswajit Das, James McMahon, Subha Sen.   

Abstract

Studies at the morphological and molecular level have found that transgenic (Tg) mice that overexpress myotrophin in the heart develop hypertrophy at the early age of 4 weeks; this condition worsens to heart failure (HF) at approximately 36 weeks. However, how the sustained effects of alteration in cytoarchitecture of the contractile machinery lead to malfunction of the normal heart remains unclear. Our data have shown that at 4 weeks, the cytoarchitecture observed in left ventricular (LV) tissue samples of Tg mice is similar to that of wild-type (WT) mice. However, as the disease progresses, cardiomyocytes show deterioration in some mitochondrial as well as myofibril features, evidenced by swelling of mitochondria, misalignment of myofibril structure, and blurring as well as breakage of Z-lines. At 36 weeks of age, Tg mice (the group in transition from hypertrophy to HF) show significant degenerative changes in cardiomyocytes, including swelling of mitochondria, disruption of the nuclear membrane, and absence of myofibril structure. Besides these, formation of myelin bodies was also observed, a feature typically found in human hearts with HF. Changes in Z-line architecture were further confirmed by alteration in the gene expression profile of desmin and tubulin, the two main cytoskeletal proteins. We thus conclude that Tg mice overexpressing myotrophin show no visible changes in the initiation phase (4 weeks); however, as the disease progresses, alterations in the cytoskeleton are found during the transition phase from hypertrophy to HF (36 weeks onward). Our data suggest that treatment for prevention/reversal of hypertrophy should start at the early stage of hypertrophy to prevent its transition to HF.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20157292     DOI: 10.1038/labinvest.2010.43

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  19 in total

Review 1.  Measuring mitochondrial function in intact cardiac myocytes.

Authors:  Elena N Dedkova; Lothar A Blatter
Journal:  J Mol Cell Cardiol       Date:  2011-09-22       Impact factor: 5.000

Review 2.  Mitochondrial fission and autophagy in the normal and diseased heart.

Authors:  Myriam Iglewski; Joseph A Hill; Sergio Lavandero; Beverly A Rothermel
Journal:  Curr Hypertens Rep       Date:  2010-12       Impact factor: 5.369

3.  Nicotinamide phosphoribosyltransferase purification using SUMO expression system.

Authors:  Trivikram R Molugu; Radu C Oita; Udeep Chawla; Sara M Camp; Michael F Brown; Joe G N Garcia
Journal:  Anal Biochem       Date:  2020-01-23       Impact factor: 3.365

Review 4.  A comprehensive review of the bioenergetics of fatty acid and glucose metabolism in the healthy and failing heart in nondiabetic condition.

Authors:  Ashish Gupta; Brian Houston
Journal:  Heart Fail Rev       Date:  2017-11       Impact factor: 4.214

5.  Systolic dysfunction in cardiac-specific ligand-inducible MerCreMer transgenic mice.

Authors:  Michael E Hall; Grant Smith; John E Hall; David E Stec
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-05-02       Impact factor: 4.733

Review 6.  Redox regulation of the actin cytoskeleton and its role in the vascular system.

Authors:  Qian Xu; Lauren P Huff; Masakazu Fujii; Kathy K Griendling
Journal:  Free Radic Biol Med       Date:  2017-03-08       Impact factor: 7.376

7.  RNA-sequencing analysis reveals new alterations in cardiomyocyte cytoskeletal genes in patients with heart failure.

Authors:  Isabel Herrer; Esther Roselló-Lletí; Miguel Rivera; María Micaela Molina-Navarro; Estefanía Tarazón; Ana Ortega; Luis Martínez-Dolz; Juan Carlos Triviño; Francisca Lago; José R González-Juanatey; Vicente Bertomeu; José Anastasio Montero; Manuel Portolés
Journal:  Lab Invest       Date:  2014-04-07       Impact factor: 5.662

8.  Disruption of MEF2C signaling and loss of sarcomeric and mitochondrial integrity in cancer-induced skeletal muscle wasting.

Authors:  Angie M Y Shum; Theodore Mahendradatta; Ryland J Taylor; Arran B Painter; Melissa M Moore; Maria Tsoli; Timothy C Tan; Stephen J Clarke; Graham R Robertson; Patsie Polly
Journal:  Aging (Albany NY)       Date:  2012-02       Impact factor: 5.682

Review 9.  Mitochondrial Bioenergetics and Dynamism in the Failing Heart.

Authors:  Giampaolo Morciano; Veronica Angela Maria Vitto; Esmaa Bouhamida; Carlotta Giorgi; Paolo Pinton
Journal:  Life (Basel)       Date:  2021-05-12

10.  In vivo quantitative mapping of human mitochondrial cardiac membrane potential: a feasibility study.

Authors:  Matthieu Pelletier-Galarneau; Yoann Petibon; Chao Ma; Paul Han; Sally Ji Who Kim; Felicitas J Detmer; Daniel Yokell; Nicolas Guehl; Marc Normandin; Georges El Fakhri; Nathaniel M Alpert
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-07-27       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.